News Release
June 10, 2010
Contact: SA Waldo Santiago
Public Information Officer
Number: (787) 277-4700

Reynaldo Landron Class Found Guilty for Conspiracy of Possession with Intent to Distribute 44 Kilos of Oxycodone

JUN 10 -- SAN JUAN, P.R. – Reynaldo Landrón Class was found guilty by a jury yesterday afternoon for participating in a conspiracy to possess with intent to distribute and dispense controlled substances, announced The Drug Enforcement Administration and Rosa Emilia Rodríguez-Vélez, United States Attorney for the District of Puerto Rico.

The Indictment charged that from on or about January, 2005, through September 4, 2007, 22 defendants, aided and abetted by each other, did knowingly and intentionally conspire, confederate and agree with each other, and with others known and unknown to the Grand Jury, to possess with intent to distribute and dispense approximately 44 kilos of Percocet/Endocet of which 676.5 grams is oxycodone a Schedule II Controlled Substance prescribed for pain; a morphine derivative and the active ingredient in painkillers such as Percodan, Percocet, Endocet, Endodan and Roxicet); and approximately 278.85 kilograms (gross weight) or more of a mixture or substance containing a detectable amount of Alprazolam (a Schedule IV controlled substance prescribed to treat panic attacks and anxiety disorders; active ingredient in Xanax).  All defendants pled guilty but Landrón Class.

The object of the conspiracy was to write multiple prescriptions for controlled substances under different names; then fill these prescriptions at three (3) particular pharmacies, Farmacia Bonneville and Farmacia Gabriella in the Municipality of Caguas and Farmacia Carimas in Levitown; and then subsequently resell the individual pills on the street for profit and financial gain.  All transactions were to be conducted in cash and, in order to hide and conceal the conspiracy; the defendants did not report the profits on tax returns submitted to the Puerto Rico Department of Treasury.

The defendant faces a sentence of 12 to 19 years in prison and $541,000 in forfeiture. 

The case was investigated by the DEA and FDA and was prosecuted by Assistant U.S. Attorney Scott Anderson.